Add Yahoo as a preferred source to see more of our stories on Google. A sign with the company logo sits outside of the headquarters campus of Eli Lilly and Company on March 17, 2024 in Indianapolis, ...
INDIANAPOLIS, April 13, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced positive topline results from the Phase 3 BRUIN CLL-322 trial of Jaypirca (pirtobrutinib), a non-covalent ...
Lilly's Jaypirca (pirtobrutinib) significantly improved progression-free survival, reducing the risk of progression or death by 80%, versus chemoimmunotherapy in patients with treatment-naïve CLL/SLL ...
"These results represent an important advancement in the care of node-positive, high-risk HR+, HER2- disease by delivering meaningful reductions in recurrence and improving survival," said Jacob Van ...
Hosted on MSN
Eli Lilly stock rises after late-stage data shows longer survival with breast cancer drug
・The study showed benefits beyond survival, including slower disease progression in certain patient groups. ・Combining the drug with Abemaciclib extended key treatment timelines compared with using it ...
Eli Lilly’s Verzenio (abemaciclib) boosted overall survival (OS) in the adjuvant breast cancer setting during a late-stage trial. In the Phase III monarchE study, (NCT02763566), Verzenio plus ...
Eli Lilly and Company (NYSE:LLY) is one of the best growth stocks to buy for the next 2 years. On August 27, Eli Lilly and Company announced that its drug, Verzenio (abemaciclib), combined with ...
Jan 22 (Reuters) - Eli Lilly and Co's stomach cancer drug ramucirumab met its primary goal of improving overall survival in a late stage-study, extending the lives of patients for more than a month ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results